Gilead Q2 2026 revenue rises 10% to $7.8 billion; GAAP loss on acquired R&D charges

Gilead reported second-quarter 2026 total revenue of $7,803 million, up 10% from a year earlier, led by HIV medicines, Trodelvy and Livdelzi. The GAAP loss was $8.45 per diluted share, driven by about $9.08 per share of acquired in-process R&D charges tied to the Arcellx, Tubulis and Ouro Medicines deals. Gilead raised the low end of its 2026 product sales guidance and lifted non-GAAP EPS guidance to a loss of $0.65 to $0.30, while cash fell to $3.2 billion from $10.6 billion at the end of 2025.

• Total revenue $7,803 million, up 10% from $7,082 million
• GAAP diluted EPS $(8.45) vs $1.56 a year earlier; non-GAAP $(6.75) vs $2.01
• HIV sales $5,693 million, up 12%; Biktarvy $3.8 billion, up 7%; Trodelvy $457 million, up 26%
• Veklury $23 million, down 81%; 2026 Veklury outlook cut to about $300 million from about $600 million
• 2026 product sales guidance $30.1 to $30.4 billion (was $30.0 to $30.4 billion); GAAP EPS guidance lowered to $(3.75) to $(3.40)
• Cash, cash equivalents and marketable debt securities $3.2 billion at June 30, 2026

SEC filing 8-K · accession 0000882095-26-000028 · sec.gov ↗